Clinical trials
ER+ Breast Cancer clinical trials
Below are recruiting er+ breast cancer clinical trials, each written for real people, not researchers. We’re tracking 554 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04360330Recruiting
MRI study in early breast cancer with specific lab markers
This study tests selected treatment decisions for women with early-stage breast cancer that has certain lab test results. It may help researchers better match care using MRI and tumor marker information.
Miami, FloridaAges 50 years+ - NCT04348747RecruitingPhase 2
Vaccine plus pembrolizumab for breast cancer in the brain
This trial studies whether a personalized immune-cell vaccine (dendritic cell vaccine) combined with pembrolizumab can help control brain metastases from certain types of breast cancer. It may help your immune system better recognize and attack cancer cells in the brain.
Tampa, FloridaAges 18 years+ - NCT04230109RecruitingPhase 2
Sacituzumab Govitecan for newly diagnosed TNBC
This trial tests a drug called sacituzumab govitecan for people with newly diagnosed triple-negative breast cancer (TNBC) that hasn't been treated yet. The drug targets cancer cells directly to try to stop them from growing.
Boston, MassachusettsAges 18 years+ - NCT04234386Recruiting
Short-course targeted radiation for early breast cancer
This trial tests a radiation plan called GammaPod to treat early breast cancer with precise targeting. It may help patients by delivering the treatment in a more focused way, while checking safety and tumor control in the smallest, well-defined cancers.
Baltimore, MarylandAges 45 years+ - NCT04084730RecruitingPhase 2
3-day radiation after breast-conserving surgery for certain breast cancers
This trial tests whether a shorter, 3-day course of partial breast radiation after surgery works as well as standard radiation for women with early-stage breast cancer. It may help reduce time in treatment while aiming to keep cancer from coming back in the treated breast area.
Norwalk, ConnecticutAges 45 years+ - NCT04090567RecruitingPhase 2
Olaparib with two partners for advanced BRCA breast cancer
This trial tests whether the drug olaparib works better when combined with cediranib or AZD6738 in people with advanced or metastatic BRCA (inherited) breast cancer. It may help shrink tumors or slow cancer growth after prior treatment with a PARP inhibitor.
Houston, TexasAges 18 years+ - NCT03936478RecruitingPhase 2
MRI-guided partial breast radiation in three short treatments
This study tests a faster, targeted type of radiation for early breast cancer, using real-time MRI to help plan and guide treatment. It may help deliver the same cancer-fighting effect while limiting radiation to the rest of the breast.
Madison, WisconsinAges 40 years+ - NCT03723928Recruiting
Blood test–guided monitoring for metastatic breast cancer treatment
This study checks whether specific blood “tumor marker” levels can help monitor how hormone receptor–positive, HER2-negative metastatic breast cancer responds to first-line therapy. It uses regular blood tests (and sometimes scans) to see if this marker-based monitoring is useful and reliable.
Anchorage, AlaskaAges 18 years+ - NCT03606967RecruitingPhase 2
Individualized vaccine added to standard treatment for metastatic triple-negative breast cancer
This Phase 2 trial tests whether adding a personalized cancer vaccine to durvalumab (an immunotherapy), tremelimumab (another immunotherapy), and chemotherapy can improve outcomes for people with metastatic triple-negative breast cancer. It may help your immune system recognize your specific tumor features.
Orange, CaliforniaAges 18 years+ - NCT02926690RecruitingPhase 1
MELK inhibitor safety study for advanced breast cancer
This Phase 1 study tests how safe a drug called an MELK inhibitor is in people with advanced breast cancer that has spread or cannot be removed with surgery. If you qualify, the study is focused on side effects and includes a special group for triple-negative breast cancer.
Norwalk, ConnecticutAges 18 years+ - NCT02732171Recruiting
Blood and bone marrow tests to track breast cancer return
This trial checks whether specific “surveillance” markers (measured from blood and bone marrow) can help predict if breast cancer comes back after standard treatments. It may help doctors monitor you more accurately and earlier if recurrence risk is high.
Philadelphia, PennsylvaniaAges 18 years+ - NCT02945579Recruiting
Testing skipping breast surgery or radiation for top responders
This trial studies whether some people with early-stage breast cancer who respond extremely well to hormone/chemo/targeted treatment can safely skip breast surgery and/or radiation. It aims to reduce side effects without increasing cancer risk in carefully selected patients.
Gilbert, ArizonaAges 30 years+ - NCT02476786RecruitingPhase 2
Hormone treatment only for older ER-positive breast cancer
This Phase 2 study tests whether using hormone (endocrine) treatment alone can control breast cancer in people age 70 and older. It targets breast cancers that are estrogen-receptor positive and HER2 negative, aiming to avoid chemotherapy-like treatments in suitable patients.
St Louis, MissouriAges 70 years+ - NCT01766297RecruitingPhase 2
Proton radiation after lumpectomy for early breast cancer
This trial studies a type of radiation made with protons to treat only part of the breast after surgery (lumpectomy) for early-stage breast cancer. It may help control the cancer while aiming to reduce radiation to surrounding tissues.
Scottsdale, ArizonaAges 50 years+ - NCT01042379RecruitingPhase 2
Adaptive drug trial for newly diagnosed breast cancer
This study tests personalized, changing treatment plans (given before surgery) to find better options for your specific breast tumor. You may be asked for extra breast-tissue testing to help match you with the most suitable study drug(s).
Birmingham, AlabamaAges 18 years+ - NCT04263298RecruitingPhase 3
Fulvestrant or capecitabine after chemo for metastatic breast cancer
This Phase 3 trial compares two medicines—fulvestrant versus capecitabine—as “maintenance” treatment after your first chemo helps control metastatic breast cancer. It aims to see which one helps people live longer with better disease control.
Guangzhou, GuangdongAges 18–75 - NCT05627960RecruitingPhase 1
Testing an antibody drug for advanced solid cancers
This Phase 1 study tests AG01, an antibody that targets a cancer protein called GP88, in people with advanced solid tumors. The goal is to find safe doses and learn whether it can help certain cancers.
Baltimore, MarylandAges 18 years+ - NCT05753657RecruitingEarly Phase 1
Testing insulin and blood sugar monitoring with pioglitazone
This early study tests whether adding pioglitazone, along with close blood-sugar (glucose/insulin) monitoring, can help control high insulin and high blood sugar in people starting alpelisib for metastatic breast cancer. It may help reduce blood-sugar side effects from alpelisib.
HaifaAges 18–85 - NCT06341894RecruitingPhase 2
Dalpiciclib and hormone therapy for early breast cancer
This trial tests a new pill (dalpiciclib) combined with hormone therapy for women with early-stage, hormone receptor positive/HER2-negative breast cancer. The goal is to see if this combination can lower the chance of cancer coming back after surgery.
Nanjing, JiangsuAges 18–75 - NCT06615466Recruiting
Short radiation course for early stage breast cancer
This trial tests a shorter, more intense radiation schedule for women with early stage breast cancer after lumpectomy. It aims to provide effective treatment with fewer visits, which may be more convenient for patients.
Beijing, Beijing MunicipalityAges 45–74 - NCT07647016RecruitingPhase 2
New Drug Combination for Advanced Hormone-Receptor-Positive Breast Cancer
This study tests two drugs together—trastuzumab deruxtecan and ivonescimab—for advanced breast cancer that is hormone-receptor-positive but HER2-negative or HER2-low. These drugs work by targeting cancer cells in different ways and may help slow or shrink tumors in patients whose cancer has progressed after earlier treatments.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07553234Recruiting
Gut Health and Side Effects from Breast Cancer Hormone Treatment
This study looks at how the bacteria in your digestive system may affect side effects from abemaciclib, a hormone-based breast cancer drug. By collecting stool samples, researchers hope to understand which patients might experience fewer problems and how to better manage treatment.
Chicago, IllinoisAges 18 years+ - NCT07524855RecruitingPhase 1
Study of a new drug for metastatic breast cancer
This trial tests an experimental drug called JNJ-101684362 (HLD-0117) for people with metastatic breast cancer that has not responded to other treatments. It may help by targeting cancer cells in a new way, and the study will check if it is safe and effective.
New Haven, ConnecticutAges 18 years+ - NCT07427394RecruitingPhase 2
Camizestrant and atirmociclib for advanced breast cancer
This trial tests two experimental drugs—camizestrant and atirmociclib—for women with advanced ER-positive breast cancer that has worsened after prior treatment. The goal is to see if the combination is safe and tolerable.
St Louis, MissouriAges 18 years+
Hear when a new ER+ Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for er+ breast cancer?
- Yes. Clin2 currently lists 554 recruiting er+ breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a er+ breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a er+ breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.